Physician profile
Joseph Schultz
NPI 1821073800
$5,822.70
in general payments reported to CMS, 2019-2025
40 companies · $938 in 2025
The $938 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $315 · 2021: $812 · 2022: $864 · 2023: $777 · 2024: $1,326 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,041.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,045.96 | 2019-2025 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $733.99 | 2019-2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $676.62 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $581.35 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $327.69 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $251.90 | 2020-2024 | Aveed, Xiaflex, Edex |
| Urogen Pharma, INC. | $247.20 | 2020-2025 | |
| Coloplast Corp | $243.71 | 2019-2025 | |
| Endo USA, INC. | $216.17 | 2024-2025 | Xiaflex, Aveed |
| Myovant Sciences INC. | $212.09 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $124.79 | 2024-2025 | Prolaris, Myrisk |
| Procept Biorobotics Corporation | $116.65 | 2024 | Aquabeam System |
| Abbvie INC. | $108.10 | 2019-2023 | Botox |
| Urovant Sciences INC | $84.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.79 | 2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $61.43 | 2023-2025 | Itind System |
| Boston Scientific Corporation | $59.33 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $54.90 | 2023-2024 | Pylarify |
| Novartis Pharmaceuticals Corporation | $54.80 | 2024-2025 | |
| 180 Medical, INC. | $53.91 | 2024 | Gentlecath Glide, Gentlecath |
| C. R. Bard, INC. & Subsidiaries | $49.79 | 2019-2025 | Magic3 Go Intermittent Urinary Catheter |
| Accord Healthcare, INC. | $48.67 | 2022-2024 | |
| Teleflex LLC | $44.70 | 2024 | Arrow |
| Baxter Healthcare | $41.14 | 2021 | |
| Tolmar, INC. | $37.33 | 2024-2025 | Jatenzo, Eligard |
| Ferring Pharmaceuticals INC. | $27.65 | 2019-2025 | Adstiladrin |
| Convatec INC. | $25.48 | 2024 | |
| Blue Earth Diagnostics | $24.95 | 2022 | |
| Immunitybio, INC. | $24.92 | 2025 | |
| Antares Pharma, INC. | $24.65 | 2023 | Nocdurna, Tlando, Xyosted |
| Hollister Incorporated | $21.83 | 2022 | |
| Rochester Medical Corporation | $21.18 | 2019 | |
| Verity Pharmaceuticals INC. | $18.88 | 2023 | Trelstar |
| Mission Pharmacal Company | $16.96 | 2024 | Uribel Tabs |
| Allergan, INC. | $16.46 | 2019 | |
| Telix Pharmaceuticals | $15.91 | 2024 | Illuccix |
| Ethicon US, LLC | $12.21 | 2021 | |
| Abc Home Medical Supply, INC. | $11.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.